



10600131-287806

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:

**David H. MUNN et al.**

Group Art Unit: 1646

Serial No.: 10/660,131

Examiner: Not Yet Assigned

Filed: September 11, 2003

For: CHEMOKINE RECEPTOR ANTAGONISTS AS THERAPEUTIC AGENTS

**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Commissioner For Patents  
*Office of Initial Patent Examination's*  
*Filing Receipt Corrections*  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

It is respectfully requested that a corrected Filing Receipt be issued in connection with the above-identified application to correct an error (copy attached). Specifically, the address of the second listed Applicant (Andrew L. Mellor) should read "Martinez, GA".

No fee is believed due, however, should any fee be involved, please charge Deposit Account No. 16-1435.

Respectfully submitted,

Date: May 4, 2004

By:   
Cynthia B. Rothschild  
Reg. No. 47,040

KILPATRICK STOCKTON, LLP  
1001 West Fourth Street  
Winston-Salem, NC 27101-2410  
(336) 607-7300



## UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail Certificate No.  
EV 216 832 599 USUNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/660,131	09/11/2003	1646	651	CCR6 (MO351/287806)	13	46	4

Cynthia B. Rothschild  
Kilpatrick Stockton LLP  
1001 West Fourth Street  
Winston-Salem, NC 27101-2400

CONFIRMATION NO. 6907

## FILING RECEIPT



\*OC000000012297575\*

Date Mailed: 04/07/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

David H. Munn, Augusta, GA;  
Andrew L. Mellor, ~~Augusta, GA~~ Martinez, GA  
Stephen C. Peiper, Augusta, GA;

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/409,804 09/11/2002

## Foreign Applications

If Required, Foreign Filing License Granted: 04/06/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

DOCKETED

FOR: CBR

Title

Chemokine receptor antagonists as therapeutic agents DUE DATE: \_\_\_\_\_

Copied from 10600131 on 06/14/2004 BY: KF

Preliminary Class

424

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).